People with myasthenia gravis (MG) have higher levels of a protein called neurofilament light chain (NfL) in their blood, especially if their symptoms are severe or start later in life, a recent study found. This means that NfL could help doctors track how the disease develops and decide on…
Neurologists consider the degree of clinical efficacy and the onset of action as the most important factors when making treatment decisions for their patients with generalized myasthenia gravis (gMG), according to a study. Still, there is variability, with some physicians considering the mode of treatment administration a more important…
A live, virtual panel at 6 p.m. EST on Oct. 23 will explore how people with myasthenia gravis (MG) can make lifestyle changes to reduce flares, have a more supportive relationship with their healthcare team, and find reliable information about the neuromuscular disorder. The free webinar, “Pushing Back…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CNP-106, an experimental treatment that Cour Pharmaceuticals is developing to reprogram the immune system in generalized myasthenia gravis (gMG). “Receiving orphan drug designation for CNP-106 is an important development and regulatory milestone for our…
Measuring changes in blood levels of two proteins — neurofilament light chain (NfL) and calprotectin (CLP) — may show how well people with generalized myasthenia gravis (gMG) respond to Ultomiris (ravulizumab) and Vyvgart (efgartigimod). That’s according to a small, real-world study in Germany that found that rising…
Black patients with generalized myasthenia gravis (gMG) face significantly higher risks of exacerbations compared with their white counterparts, according to a retrospective analysis of healthcare insurance claims from a U.S. database. Exacerbations refer to the worsening of existing symptoms or the appearance of new ones. “Interventions aimed at addressing…
A European Medicines Agency (EMA) committee recommended that the agency approve nipocalimab as an add-on treatment for generalized myasthenia gravis (gMG) patients aged 12 and older who have antibodies against acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). The Committee for Medicinal Products for Human Use (CHMP) recommendation comes a…
People who begin experiencing symptoms of generalized myasthenia gravis (gMG) at the age of 65 or older tend to have a more aggressive initial disease course — but a more favorable prognosis over the following two years. That’s according to a new study from Greece that investigated the short-term…
People with refractory myasthenia gravis (MG) who fail to respond to several treatments may be effectively treated with Vyvgart (efgartigimod alfa-fcab), regardless of the type of self-reactive antibodies they carry. That’s according to a systematic review and meta-analysis, which showed that patients treated with Vyvgart saw their symptoms…
Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are generally safe and effective for easing symptoms of generalized myasthenia gravis (gMG) when used in everyday clinical practice. That’s according to data from the MG SPOTLIGHT Registry (NCT04202341), which was established to assess the long-term effectiveness of both therapies in…
Get regular updates to your inbox.
